Natco Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma has submitted a compliance certificate under SEBI Regulation 74(5) for the quarter ended June 30, 2025. The certificate, issued by the company's Registrar (Venture Capital and Corporate Investments Private Limited), confirms that physical share certificates received for dematerialization have been properly cancelled and the names of the depositories (NSDL and CDSL) have been updated as the registered owners within 15 days. This is a standard quarterly compliance filing required by SEBI to ensure proper handling of share conversion requests from physical to electronic form.
This is a routine regulatory compliance filing with no material impact on the company's financials or stock price. It merely confirms the registrar has followed proper procedures for processing dematerialization requests during the quarter.